Reduced glomerular filtration rate but sustained virologic response in HIV/hepatitis B co-infected individuals on long-term tenofovir

Journal of Viral Hepatitis

Volumn 16, Issue 7, 2009, Pages 471-478

  Tan, L K K ^a   Gilleece, Y ^b   Mandalia, S ^a   Murungi, A ^a   Grover, D ^c   Fisher, M ^b   Atkins, M ^a   Nelson, M ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^c CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Drug efficacy; Hepatitis B; HIV; Renal toxicity; Tenofovir disoproxil fumarate

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CREATININE; HEPATITIS B(E) ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR DISOPROXIL; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOACIDURIA; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; BLOOD LEVEL; BONE PAIN; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG WITHDRAWAL; FANCONI RENOTUBULAR SYNDROME; FEMALE; FOLLOW UP; GENE MUTATION; GLOMERULUS FILTRATION RATE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPOPHOSPHATEMIA; KIDNEY DYSFUNCTION; LONG TERM CARE; MALE; MIXED INFECTION; OSTEOPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

ADENINE; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HEPATITIS B; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 67650441920     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01084.x     Document Type: Article

References (36)

1. World Health Organisation. Hepatitis B. WHO, 2002. http://www.who.int/ csr/disease/hepatitis/HepatitisB-whocdscsrlyo2002-2.pdf (accessed 24 September 2007).
2. UNAIDS. Report on the global HIV/AIDS epidemic 2008. http://data.unaids. org/pub/GlobalReport/2008/JC1510-2008GlobalReport-en.zip (accessed 1st October 2008).
3. World Health Organisation. Chapter 7: Management of hepatitis B and HIV coinfection. In : Eramova I, Matic S, Munz M, eds. HIV/AIDS Treatment and Care. Clinical Protocols for the WHO European. Geneva : World Health Organisation, 2007.
4. Thio CL. Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. Semin Liver Dis 2003 23 (2 125 136. (Pubitemid 36666682)
5. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007 45 (4 1056 1075. (Pubitemid 46646501)
6. Gazzard B, BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). HIV Med 2005 6 (Suppl 2 1 61. (Pubitemid 41038585)
7. Ying C, De Clercq E, Neyts J. Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture. J Viral Hepat 2000 7 (1 79 83. (Pubitemid 30139856)
8. Nelson M, Portsmouth S, Stebbing J et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS 2003 17 : F7 F10.
9. Benhamou Y, Fleury H, Trimoulet P et al. Anti-hepatitis B efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 2006 43 (3 548 555.
10. Gallant JE, Deresinski S. Tenofovir disoproxil fumarate. Clin Infect Dis 2003 37 (7 944 950. (Pubitemid 37267211)
11. Karras A, Lafaurie M, Furco A et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003 36 (8 1070 1073. (Pubitemid 36513295)
12. Jones R, Stebbing J, Nelson M et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J Acquir Immune Defic Syndr 2004 37 (4 1489 1495. (Pubitemid 39602339)
13. Blaas S, Schneidewind A, Glück T, Salzberger B. Acute renal failure in HIV patients with liver cirrhosis receiving tenofovir: a report of two cases. AIDS 2006 20 (13 1786 1787. (Pubitemid 44299375)
14. Gilleece Y, Nelson M, Clarke A et al. Tenofovir in the treatment of Hepatitis b/HIV co-infected individuals [Abstract]. Int Conf AIDS 2004 15 : Abstract no. MoPeB3298.
15. Levey AS, Greene T, Kusek JW, Beck GJ, Group MS. A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. J Am Soc Nephrol 2000 11 : A0828.
16. Levey AS, Coresh J, Balk E et al. National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003 139 (2 137 147.
17. Soriano V, Puoti M, Peters M et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 2008 22 (12 1399 1410.
18. Nunez M, Perez-Olmeda M, Diaz B, Rios P, Gonzalez-Lahoz J, Soriano V. Activity of tenofovir on hepatitis B virus replication in HIV-coinfected patients failing or partially responding to lamivudine. AIDS 2002 16 : 2352 2354. (Pubitemid 35449029)
19. Bochet M, Tubianan R, Benhamou Y. Tenofovir disoproxil fumarate suppresses lamivudine-resistant HBV replication in patients coinfected with HIV/HBV [Abstract]. 9th Conference on Retroviruses and Opportunistic Infection, Seattle, 2002 [Abstract 675].
20. Cooper D, Cheng A, Coakley D. Anti-HBV activity of tenofovir disoproxil fumarate in lamivudine-experienced HIV/HBV coinfected patients [Abstract]. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, 2002 [Abstract 124].
21. Ristig M, Crippin J, Aberg J. Tenofovir dipivoxil fumarate therapy for chronic hepatitis B in HIV/HBV-coinfected individuals for whom interferon alpha and lamivudine therapy have failed. J Infect Dis 2002 186 : 1844 1847.
22. Dore GJ, Cooper DA, Pozniak AL et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004 189 (7 1185 1192. (Pubitemid 38457242)
23. Mauss S, Berger F, Henke J, Hegener P, Athman C, Schmutz G. Long term suppression of HBV by tenofovir in HIV/HBV-coinfected patients [Abstract]. 3rd International Workshop on HIV and Hepatitis Co-infection, Paris, 2007 Abstract 38 J, Camino N, Rodés B et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005 10 (6 727 734.
24. Fux C, Simcock M, Wolbers M et al. Tenofovir treatment is associated with a decrease in calculated glomerular filtration rates in a large observational cohort [Abstract]. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007 [Abstract 834].
25. Moore R, Keruly J, Gallant J. Tenofovir and renal dysfunction in clinical practice [Abstract]. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007 [Abstract 832].
26. Nelson MR, Katlama C, Montaner JS et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007 21 (10 1273 1281. (Pubitemid 46883481)
27. Goicoechea M, Liu S, Best B et al. Increased renal impairment in patients receiving TDF + PI vs TDF + NNRTI [Abstract]. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007 [Abstract 835].
28. Wai H, Katsivas T, Ballard C, Barber E, Mathews C. Risk factors for tenofovir-associated nephrotoxicity identified in an HIV clinic cohort [Abstract]. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007 [Abstract 833].
29. Wyatt CM, Arons RR, Klotman PE, Klotman ME. Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality. AIDS 2006 20 (4 561 565. (Pubitemid 43731600)
30. Wyatt CM, Winston JA, Malvestutto CD et al. Chronic kidney disease in HIV infection: an urban epidemic. AIDS 2007 21 (15 2101 2103. (Pubitemid 47462160)
31. Franceschini N, Napravnik S, Finn WF, Szczech LA, Eron JJ Jr. Immunosuppression, hepatitis C infection, and acute renal failure in HIV-infected patients. J Acquir Immune Defic Syndr 2006 42 (3 368 372. (Pubitemid 44050017)
32. Franceschini N, Napravnik S, Eron JJ Jr., Szczech LA, Finn WF. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int 2005 67 (4 1526 1531. (Pubitemid 40463131)
33. Ng CK, Chan MH, Tai MH, Lam CW. Hepatorenal syndrome. Clin Biochem Rev 2007 28 (1 11 17.
34. Wadei HM, Mai ML, Ahsan N, Gonwa TA. Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol 2006 1 (5 1066 1079.
35. Naicker S, Fabian J, Naidoo S, Wadee S, Paget G, Goetsch S. Infection and glomerulonephritis. Semin Immunopathol 2007 29 (4 397 414. (Pubitemid 350077259)
36. Myers GL, Miller WG, Coresh J et al. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem 2006 52 (1 5 18. (Pubitemid 43032461)